Search

Drinabant

AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.

Laquinimod

It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.

Honey

It is not an approved drug.

Cefditoren

It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

Dihydroxymethoxychalcone

Cardamonin's name comes from the fact that it can be found in cardamom spice. … Cardamonin (also known as Dihydroxymethoxychalcone), as shown by the increasing number of publications, has received growing attention from the scientific community due to the expectations toward its benefits

Canertinib

Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET. … Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.

APD668

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also av...

Imidafenacin

It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical. … It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.

Tylosin

It has a broad spectrum of activity against Gram-positive organisms and a limited range of Gram-negative organisms. Tylosin is produced as a fermentation product of Streptomyces fradiae.

Sodium phosphate, dibasic